Kiadis Pharma obtains up to €15 mil­lion debt financ­ing from Kreos Capital

Amsterdam-Duivendrecht, The Netherlands, August 17, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive prod­ucts to make bone mar­row trans­plan­ta­tions safer and more effec­tive for patients suf­fer­ing from blood can­cers and inher­it­ed blood dis­or­ders, today announces that it has obtained a debt facil­i­ty of up to €15 mil­lion from Kreos Capital.
The loan con­sists of two tranch­es, with the first tranche of €10 mil­lion imme­di­ate­ly drawn down and a sec­ond tranche of €5 mil­lion upon the com­pa­ny rais­ing €20 mil­lion in addi­tion­al funds. Kiadis Pharma will use the loan to advance the devel­op­ment of the Company’s ATIR prod­ucts, for gen­er­al cor­po­rate pur­pos­es and to repay the remain­ing €5.3 mil­lion of exist­ing Dutch Government Loans.
Arthur Lahr, CEO of Kiadis Pharma, com­ment­ed: “We are pleased with this non-dilu­tive debt fund­ing from Kreos Capital, Europe’s largest provider of debt-financ­ing solu­tions to high-growth com­pa­nies. The loan allows us to refi­nance an exist­ing loan with improved terms and extends our cash run­way, as we progress towards poten­tial­ly obtain­ing mar­ket­ing approval for ATIR101™ in the European Union in the sec­ond half of 2018.
Maurizio PetitBon, General Partner of Kreos Capital, com­ment­ed: “We are pleased to be sup­port­ing Kiadis Pharma, a com­pa­ny that is advanc­ing the field of allo­gene­ic hematopoi­et­ic stem cell trans­plan­ta­tions and is improv­ing the out­comes of patients suf­fer­ing from blood can­cers and inher­it­ed blood dis­or­ders. The flex­i­ble fund­ing pro­vid­ed by Kreos will pro­vide a strong foun­da­tion for Kiadis to advance the devel­op­ment of ATIR101™.

Leave a Reply

Your email address will not be published. Required fields are marked *